This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Jim Cramer's 'Mad Money' Recap: Faith in the Market

Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.


NEW YORK (TheStreet) -- You have to have faith if you're going to invest in the stock market, Jim Cramer told his "Mad Money" viewers Tuesday. Investors need to believe the companies they invest in will deliver on their promises. Fortunately, for some companies believing is not hard at all.

That's certainly the case with Regeneron (REGN), Cramer told viewers. This is one company that's repeatedly gotten it right despite analysts' predictions that the upside has already been "baked in" to the share price. Regeneron has deliverered a 5,900% return over the past nine years.

Allergan (AGN) is another example of faith, Cramer continued. This stock fell last year from $115 to $85 on fears of generic drug competition. But six months ago Allergan's CEO appeared on Mad Money, telling viewers that the generic challenges were not a problem. Allergan's stock is up 34% since that appearance.

Cramer also offered a tip of the hat to Google (GOOG) for its acquisition of Nest, and Hain Celestial (HAIN) for its purchase of Tilda, makers of basmati rice. He was also bullish on Tesla Motors (TSLA), a company that's still impossible to value but also one with a CEO who's impossible to ignore.

When can faith go awry? Cramer said he was wrong to trust Timken (TKR), which delivered the worst pre-announcement this year, and also GameStop (GME), which neglected to mention its significant short-term challenges -- news that sent that stock down 19% in today's trading.

Executive Decision: Leonard Schleifer

For his "Executive Decision" segment, Cramer spoke with Leonard Schleifer, president and CEO of Regeneron, which today announced continued successes with its drug Eyelea as well as a promising pipeline that includes drugs for high cholesterol, arthritis and asthma among others.

Schleifer said that despite analysts' calls to the contrary, Eyelea has lots of room to grow thanks to favorable demographics, new geographies and, he hopes, new indications for the drug later in 2014. Regeneron is also making progress on its anti-cholesterol drug, for which the company hopes to file for approval early next year.

In addition, Regeneron is developing promising treatments for the epidemic of allergic diseases that are developing, as well as treatments for genetic ailments.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,750.54 +289.22 1.76%
S&P 500 1,956.60 +29.49 1.53%
NASDAQ 4,464.1870 +81.34 1.86%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs